Category: News
Participation in the Fit4Start program
OrganoTherapeutics is very happy to announce that we have been selected as participants in the Luxembourgish Fit4Start program. The selection has been widely covered by the press in Luxembourg. There are articles in Paperjam, Wort, Chronicle, Letzebuerger Journal and Silicon Luxembourg The Luxembourgish Minister of the Economy about Fit4Start:
Read More
Joining the Creative Destruction Lab program
We are very happy to announce that OrganoTherapeutics has been accepted into the Creative Destruction Lab (CDL) program (https://www.linkedin.com/company/creative-destruction-lab/). We are participating in the Health program which will be held in Oxford. Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- […]
Read More
Finding new treatment targets in Parkinson’s using a patient-based model of RNA mis-splicing
Today a new study with the title “Finding new treatment targets in Parkinson’s using a patient-based model of RNA mis-splicing” was published in Science Translational Medicine (Abstract below). We are very proud that the patient specific midbrain organoid model, which is licensed by OrganoTherapeutics has been used successfully in this […]
Read More
Joing MassChallenge Texas
The OrganoTherapeutics team is very excited to announce that we have been accepted in the 2020 cohort of the MassChallenge program. We will be part of the MassChallenge Texas cohort in Houston. We particularly thank the University of Luxembourg and the University of Luxembourg Incubator for their continuous support. Furthermore, […]
Read More
Machine learning-assisted neurotoxicity prediction in human midbrain organoids
We use human midbrain organoids to investigate if toxins can induce Parkinson`s disease like phenotypes. Additionally, this can be used as a platform technology to test if small molecules can ameliorate the negative effects of these toxins. A recent publication from the University of Luxembourg shows how the midbrain organoid […]
Read More
Finalist in the Start-up Stadium
We are very proud to have been selected as finalist in the Start-up Stadium at the Bio International Convention. This year the convention will be entirely virtual. But nevertheless, we will present our latest developments in brain organoid technology and development of new treatments for Parkinson`s disease. We will also […]
Read More
Winning at the Science4Life Venture Cup
The team of OrganoTherapeutics is proud to announce that we were successful in the Science4Life Venture Cup. This is a very nice recognition showing us that we are on the right track. Here is the press release (in German): https://www.science4life.de/presseentry/konzeptpraemierung-2020/#presse-detail-anchor
Read More
OrganoTherapeutics and InnoSer to Offer Midbrain Organoids
OrganoTherapeutics and InnoSer are joining forces to make midbrain organoids available for screening and development of pharmaceutical compounds. This partnership will enable providing midbrain organoids commercially as a platform for Parkinson’s disease research. CEO of InnoSer, Jan Bartels, says: “We already work with organoids for cancer and we are developing […]
Read More
Luxemburger Wort writes about OrganoTherapeutics
Today, the Luxembourgish newspaper “Luxemburger Wort” published a long article describing the attempts of OrganoTherapeutics to use human midbrian organoids (mini-brains) to develop new therapies against Parkinson’s disease. The article can be found here: https://www.wort.lu/de/business/start-up-organotherapeutics-gehirn-aus-der-petrischale-5e297596da2cc1784e354964
Read More
Alan and Helene Goldberg grant
We are very happy to announce that our project “Analysis of Parkinson’s disease associated alpha-Synuclein aggregate toxicity in patient specific brain organoids” has been selected for funding via the Alan and Helene Goldberg grant (CAAT grant). This is a great achievement for OrganoTherapeutics and we are looking forward to start […]
Read More